xm:徐田锋
xb:男
zc:研究员
xl:博士
dh:
cz:
dzyj:tfxu@simm.ac.cn
grzy:
zjlb:研究员
zw:课题组长
txdz:上海市浦东新区张江高科技园区海科路501号
grjj:徐田锋，上海药物研究所研究员，课题组长。2014年于中科院广州生物医药与健康研究院获得药物化学博士学位，同年加入密歇根大学-安娜堡校区癌症中心从事博士后研究，于2019年3月加入上海药物研究所。主要从事药物化学研究，工作内容主要集中在药物分子合理设计，活性先导化合物结构优化及成药性修饰。相关工作已经发表在Angew. Chem. Int. Ed, J. Med. Chem等国际知名学术期刊上，获得了3项中国发明专利授权，并参与申请了4项美国发明专利。
yjfx:1. 可诱导蛋白质降解的小分子药物的设计与开发

2. 小分子激酶抑制剂的设计与开发

dblz:1.Aguilar, A.#; Zheng, K.#; Xu, T.#; Xu, S.#; Huang, L.#; Fernández-Salas, E.; Liu, L.; Bernard, D.; Harvey, K.; Foster, C.; McEachern, D.; Stuckey, J.; Chinnaswamy, K.; Delproposto, J.; Kampf, J.; and Wang, S., Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein–Protein Interaction, J Med Chem. 2019, 62 (13), 6015-6034. (#共同第一作者)

2.Xu, S.#; Aguilar, A.#; Xu, T.#; Zheng, K.#; Huang, L.#; Stuckey, J.; Chinnaswamy, K.; Bernard, D.; Fernández-Salas, E.; Liu, L., Wang, M.; McEachern, D.; Przybranowski, S.; Foster, C.; Wang, S., Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein–Protein Interaction, Angew Chem Int Edit. 2018, 57 (6), 1601-1605.

3.Xu, T.#; Peng, T.#; Ren, X.#; Zhang, L.; Yu, L.; Luo, J.; Zhang, Z.; Tu, Z.; Tong, L.; Huang, Z.; Lu, X.; Geng, M.; Xie, H.; Ding, J.; Ding, K., C5-substituted pyrido [2, 3-d] pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR T790M mutant, MedChemComm. 2015, 6(9), 1693-1697.

4.Xu, T.#; Zhang, L.#; Xu, S.; Yang, C.; Luo, J.; Ding, F.; Lu, X.; Liu, Y.; Tu, Z.; Li, L.; Pei, D.; Cai, Q.; Li, H.; Ren, X.; Wang, S.; Ding, K., Pyrimido[4,5-d]pyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine790 to Methionine790 (T790M) Mutants, Angew Chem Int Edit. 2013, 52(32),8387-8390.

5.Han, X.#; Wang, C.#; Qin, C.#; Xiang, W.#; Fernandez-Salas, E.; Yang, C.-Y.; Wang, M.; Zhao, L.; Xu, T.; Chinnaswamy, K.; Delproposto, J.; Stuckey, J.; Wang, S., Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019, 62 (2), 941-964 .

6.Yu, L.; Huang, M.; Xu, T.; Tong, L.; Yan, X.; Zhang, Z.; Xu, Y.; Yun, C.; Xie, H.; Ding, K.; Lu, X., A structure-guided optimization of pyrido [2, 3-d] pyrimidin-7-ones as selective inhibitors of EGFR L858R/T790M mutant with improved pharmacokinetic properties, Eur J Med Chem. 2017, 126, 1107-1117.

jyjl:2009.08-2014.07中国科学院广州生物医药与健康研究院，药物化学，博士